A study of natural IgG antibodies against ATP-binding cassette subfamily C member 3 in oral squamous cell carcinoma.


Journal

Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598

Informations de publication

Date de publication:
2019
Historique:
entrez: 23 8 2019
pubmed: 23 8 2019
medline: 11 2 2020
Statut: ppublish

Résumé

ATP-binding cassette subfamily C member 3 (ABCC3) is involved in multidrug resistance and is overexpressed in some solid tumors. Recent work revealed an increase in circulating anti-ABCC3 antibodies in lung and esophageal cancers. This in vitro study was undertaken to investigate the effects of the natural IgG antibody against the ABCC3-derived peptide antigen on proliferation of oral squamous cell carcinoma (OSCC) cells and augment the development of efficient and effective treatments in patients with OSCC. An in-house enzyme-linked immunosorbent assay was applied to detect anti-ABCC3 IgG antibody in human plasma. Two OSCC cell lines, CAL27 and SCC15, were cultured with 20% plasma either positive or negative for anti-ABCC3 IgG. Cell proliferation was quantified by the CCK-8 method, and cell apoptosis and cell cycle distribution were analyzed by flow cytometry. The expression of the ABCC3 gene in the cell lines was analyzed by reverse transcriptase quantitative real-time polymerase chain reaction. The results showed that plasma anti-ABCC3 IgG significantly inhibited the proliferation of CAL27 cells but not SCC15 cells, although ABCC3 was expressed in both cell lines. The proportion of apoptotic cells was significantly higher in CAL27 cells treated with anti-ABCC3 IgG-positive plasma than in those treated with IgG-negative plasma. Cell cycle progression was arrested in CAL27 cells treated with anti-ABCC3 IgG-positive plasma. Our data suggest that human plasma anti-ABCC3 IgG may be a promising agent in anti-OSCC therapy, although further studies are needed to arrive at a definitive conclusion.

Identifiants

pubmed: 31436253
pii: JCanResTher_2019_15_4_921_264279
doi: 10.4103/jcrt.JCRT_150_18
doi:

Substances chimiques

Autoantibodies 0
Biomarkers, Tumor 0
Immunoglobulin G 0
Multidrug Resistance-Associated Proteins 0
multidrug resistance-associated protein 3 1YV0492L5Z

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

921-926

Déclaration de conflit d'intérêts

None

Auteurs

Xiu Liu (X)

Beijing Institution of Dental Research, Beijing Stomatological Hospital, Capital Medical University, Beijing, People's Republic of China.

Zhicheng Huang (Z)

Department of Radiology, Jilin Cancer Hospital, Changchun, People's Republic of China.

Ziyi He (Z)

Department of Transfusion Research, Dongguan Blood Center, Dongguan, People's Republic of China.

Qingyong Meng (Q)

Institute of Laboratory Medicine, Guangdong Medical University, Dongguan, People's Republic of China.

Xiaoyu Wang (X)

Beijing Institution of Dental Research, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.

Ying Hu (Y)

Beijing Institution of Dental Research, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH